Business Context and Reporting Period
This Form 8-K was filed by Owl Rock Capital Corporation (trading symbol: ORCC) on July 17, 2020, reporting an event that occurred on July 16, 2020. The registrant is a Maryland corporation with principal executive offices in New York, NY. The filing is not a periodic financial report but a current report regarding a specific corporate event.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial data point disclosed is the issuance of new debt:
- New Debt Issuance: $500 million aggregate principal amount.
- Instrument: 4.250% Notes due 2026.
- Underwriters: BofA Securities, Inc. as representative.
Material Changes
The material change reported is the execution of an underwriting agreement for the sale of the $500 million Notes. This transaction was conducted pursuant to the Company's effective shelf registration statement on Form N-2 (Registration No. 333-239775). The filing does not provide comparative data against prior periods as it is not a financial results report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the company's operations. The document notes that the description of the Underwriting Agreement is qualified in its entirety by reference to the full text of the agreement filed as Exhibit 1.1. No unusual items or contingencies are detailed in the text of this summary.
Investor Verification Checklist
- Verify the full terms of the Underwriting Agreement in Exhibit 1.1 attached to the filing.
- Confirm the use of proceeds from the $500 million Notes issuance in the final prospectus supplement dated July 16, 2020.
- Review the Company's latest periodic reports (10-K or 10-Q) for existing debt levels and liquidity metrics not included in this 8-K.
- Check for any subsequent filings regarding the pricing or closing of the Notes if not fully detailed in the prospectus supplements.